ATE310018T1 - Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung - Google Patents

Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung

Info

Publication number
ATE310018T1
ATE310018T1 AT99945505T AT99945505T ATE310018T1 AT E310018 T1 ATE310018 T1 AT E310018T1 AT 99945505 T AT99945505 T AT 99945505T AT 99945505 T AT99945505 T AT 99945505T AT E310018 T1 ATE310018 T1 AT E310018T1
Authority
AT
Austria
Prior art keywords
protein
comparable
kinase activity
kid
vitro kinase
Prior art date
Application number
AT99945505T
Other languages
English (en)
Inventor
Michele A Mctigue
Chris Pinko
Camran V Parast
Michael R Gehring
Chen-Chen Kan
Drive Watson
Krzysztof Appelt
John A Wickersham
Richard Edward Showalter
Anna-Maria Tempcyzk-Russell
Barbara Mroczkowski
Jesus Ernesto Villafranca
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Application granted granted Critical
Publication of ATE310018T1 publication Critical patent/ATE310018T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99945505T 1998-09-08 1999-09-07 Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung ATE310018T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9950398P 1998-09-08 1998-09-08
PCT/US1999/020319 WO2000014105A1 (en) 1998-09-08 1999-09-07 Modifications of the vegf receptor-2 protein and methods of use

Publications (1)

Publication Number Publication Date
ATE310018T1 true ATE310018T1 (de) 2005-12-15

Family

ID=22275320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99945505T ATE310018T1 (de) 1998-09-08 1999-09-07 Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung

Country Status (10)

Country Link
US (5) US6316603B1 (de)
EP (1) EP1109823B1 (de)
JP (1) JP2002534058A (de)
KR (1) KR100442221B1 (de)
AT (1) ATE310018T1 (de)
AU (1) AU760008B2 (de)
CA (1) CA2340598A1 (de)
DE (1) DE69928411D1 (de)
ES (1) ES2252972T3 (de)
WO (1) WO2000014105A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE310018T1 (de) * 1998-09-08 2005-12-15 Agouron Pharma Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung
AU5623801A (en) * 2000-03-29 2001-10-08 Max Planck Gesellschaft 3d structure of polypeptides containing a tpr-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said peptides
DK1294929T3 (da) * 2000-06-07 2005-12-12 Ortho Mcneil Pharm Inc Fremgangsmåde til påvisning af VEGF-kinasedomænemodulatorer
MXPA03001452A (es) * 2000-08-18 2004-05-04 Agouron Pharma Hidroximino-fluorenos heterociclicos y su uso para la inhibicion de las proteinas cinasas.
SI2311825T1 (sl) 2000-12-21 2016-02-29 Novartis Ag Pirimidinamini kot angiogenetski modulatorji
WO2003057173A2 (en) * 2002-01-07 2003-07-17 Sequoia Pharmaceuticals Broad spectrum inhibitors
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
US20040229293A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
AU2004225439A1 (en) * 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
WO2004092217A1 (en) * 2003-04-17 2004-10-28 Pfizer Inc. Crystal structure of vegfrkd: ligand complexes and methods of use thereof
EP1697508A2 (de) * 2003-12-05 2006-09-06 Vertex Pharmaceuticals, Inc. Kristallstruktur der interleukin-2 tyrosin kinase (itk) und bindungsstellen davon
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2023164224A1 (en) * 2022-02-28 2023-08-31 The Board Of Trustees Of The Leland Stanford Junior University Functionalized nanoclusters and their use in treating bacterial infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
US6043211A (en) * 1988-02-02 2000-03-28 The Regents Of The University Of California Method for inhibiting the activity of a platelet-derived growth factor receptor binding protein
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
CZ291047B6 (cs) 1992-10-28 2002-12-11 Genentech, Inc. Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
NZ500530A (en) 1997-04-25 2001-12-21 Collateral Therapeutics Truncated VEGF-B, VEGF-C, VEGF-3, PlGF, VRF-2, poxvirus ORF-1 and ORF-2 proteins
ATE310018T1 (de) * 1998-09-08 2005-12-15 Agouron Pharma Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung
WO2002036785A1 (en) * 2000-10-30 2002-05-10 Protein Crystal Co., Ltd. Protein complexes and process for producing the same

Also Published As

Publication number Publication date
KR20010086386A (ko) 2001-09-10
US6753416B2 (en) 2004-06-22
US6316603B1 (en) 2001-11-13
US6849721B2 (en) 2005-02-01
EP1109823A4 (de) 2003-06-18
US6794146B2 (en) 2004-09-21
KR100442221B1 (ko) 2004-07-30
US20020127538A1 (en) 2002-09-12
EP1109823B1 (de) 2005-11-16
US20020051965A1 (en) 2002-05-02
AU5809399A (en) 2000-03-27
US6784285B1 (en) 2004-08-31
DE69928411D1 (de) 2005-12-22
JP2002534058A (ja) 2002-10-15
WO2000014105A1 (en) 2000-03-16
AU760008B2 (en) 2003-05-08
CA2340598A1 (en) 2000-03-16
US20020164641A1 (en) 2002-11-07
ES2252972T3 (es) 2006-05-16
EP1109823A1 (de) 2001-06-27

Similar Documents

Publication Publication Date Title
Nybakken et al. Hedgehog signal transduction: recent findings
ATE310018T1 (de) Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung
Yan et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia
Dothager et al. Advances in bioluminescence imaging of live animal models
Holt et al. A chemical-genetic strategy implicates myosin-1c in adaptation by hair cells
Alloway et al. A role for the light-dependent phosphorylation of visual arrestin
Xu et al. Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5
Milán et al. Regulation of LIM homeodomain activity in vivo: a tetramer of dLDB and apterous confers activity and capacity for regulation by dLMO
Chung et al. Characterization of the chicken β-globin insulator
Goebel et al. Structural characterization of an activin class ternary receptor complex reveals a third paradigm for receptor specificity
Holcik et al. Four highly stable eukaryotic mRNAs assemble 3′ untranslated region RNA–protein complexes sharing cis and trans components
Jia et al. Phosphorylation by double-time/CKIε and CKIα targets cubitus interruptus for Slimb/β-TRCP-mediated proteolytic processing
Liu et al. Overlapping functions between XLF repair protein and 53BP1 DNA damage response factor in end joining and lymphocyte development
Lamba et al. A novel role for the forkhead transcription factor FOXL2 in activin A-regulated follicle-stimulating hormone β subunit transcription
Graham et al. The Conserved Arginine in Rho-GTPase-Activating Protein Is Essential for Efficient Catalysis but Not for Complex Formation with Rho⊙ GDP and Aluminum Fluoride
Nowak et al. The transcription factor Yin Yang 1 is an activator of BACE1 expression
Lai et al. Bovine papillomavirus E5 protein induces oligomerization and trans-phosphorylation of the platelet-derived growth factor β receptor
Gutjahr et al. Analysis of the gooseberry locus in Drosophila embryos: gooseberry determines the cuticular pattern and activates gooseberry neuro
Zhang et al. Evidence that dim1 associates with proteins involved in pre-mRNA splicing, and delineation of residues essential for dim1 interactions with hnRNP F and Npw38/PQBP-1
ATE291618T1 (de) Dna codierend für den menschlichen 5-ht 1f rezeptor und ihre verwendung
Lödige et al. Nuclear export determines the cytokine sensitivity of STAT transcription factors
US20100311811A1 (en) Rna-mediated epigenetic regulation of gene transcription
Vincentz et al. Exclusion of Dlx5/6 expression from the distal-most mandibular arches enables BMP-mediated specification of the distal cap
Shaffer et al. Heterochromatin protein 2 (HP2), a partner of HP1 in Drosophila heterochromatin
Kwon et al. Brca2 abrogation engages with the alternative lengthening of telomeres via break‐induced replication

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties